Form 4: Elanco Executive Ellen de Brabander Reports Stock Transactions

Ellen de Brabander, an Executive Vice President at Elanco Animal Health, reports the acquisition and disposal of company stock and stock options.

Summary

• On March 1, 2024, Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco Animal Health Inc., reported transactions involving Elanco's common stock.
• She acquired 31,847 shares of common stock through a grant of restricted stock units at $0 per share, vesting in three equal installments on March 1, 2025, 2026, and 2027.
• She also disposed of 9,774 shares at $16.03 per share to cover tax liabilities related to the vesting of previously awarded restricted stock units.
• Additionally, she was granted stock options for 69,456 shares at an exercise price of $16.03, vesting in three equal installments on March 1, 2025, 2026, and 2027.
• Following these transactions, de Brabander directly owns 114,886 shares of Elanco common stock and holds options for 69,456 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock transactions. The grants are positive, but the disposal to cover taxes is neutral.

Positives

• The grant of restricted stock units and stock options to a key executive aligns her interests with the long-term performance of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options and restricted stock units suggests a multi-year commitment from the executive.

Industry Context

Executive stock transactions are common in publicly traded companies and are often used to incentivize and retain key personnel. The details of these transactions are closely watched by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices in the animal health and pharmaceutical industries.
• Companies like Zoetis and Merck Animal Health also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting equity.
• Employees may view the executive's stock ownership as a positive sign of commitment to the company's success.

Key Dates